Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06355986 · ClinicalTrials.gov registry record · NA
Computerized Decision Support to Prevent Stroke in Atrial Fibrillation
A NA study, sponsored by Brigham and Women's Hospital.
- Not yet
- Registry status
- NA
- Development phase
- 2,500
- Enrollment target
NCT06355986: Clinical Trial NA study, sponsored by Brigham and Women's Hospital.
NCT06355986 is a NA study that has not yet begun recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 2,500 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06355986, a NA study, has not yet begun recruiting, sponsored by Brigham and Women's Hospital.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 2,500 participants
- Enrollment target
Study Summary
Atrial fibrillation (AF) is the most preventable cause of stroke. However, despite widely available risk stratification tools, numerous options for oral anticoagulation, and evidence-based practice guidelines, anticoagulation for stroke prevention in AF is consistently under-prescribed. In a pair of observational cohort analyses within the Mass General Brigham (MGB) health system, prescription of anticoagulation for stroke prevention in AF was less frequent in ambulatory clinic patients than in those who were hospitalized at the time of assessment (46.9% vs. 57.2%). Two single academic medical center randomized controlled trials demonstrated success for increasing adherence to guideline recommendations for stroke prevention in AF. To address the feasibility and impact of a computerized decision support (CDS) strategy in the non-tertiary care, community medical center setting, this study will involve a multicenter, cluster-randomized controlled trial of a more sophisticated CDS focused not only on implementation stroke prevention but also on bleeding risk assessment and management.
Primary Outcome
The primary efficacy outcome will be determined by review of the Electronic Health Record (EHR) medication documentation for prescription of anticoagulation by 90 days after enrollment. These data will be collected in the form of a BPA report and then confirmed by independent data abstractors.
Interventions
- BEHAVIORAL Alert-based computerized decision support
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2026-12-30 |
| Est. Completion | 2027-07-30 |
| Phase | NA |
What is known before NCT06355986 opens enrollment
NCT06355986 is an interventional study that assigns participants to a tested intervention. Its 2,500 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% higher).
The record links to 0 conditions, and to 1 intervention - of which Alert-based computerized decision support is the first listed.
NCT06355986 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06355986 about?
NCT06355986 is a clinical study titled "Computerized Decision Support to Prevent Stroke in Atrial Fibrillation". Atrial fibrillation (AF) is the most preventable cause of stroke. However, despite widely available risk stratification tools, numerous options for oral anticoagulation, and evidence-based practice guidelines, anticoagulation for stroke prevention in AF is consistently under-prescribed. In a pair of...
What is the current status of trial NCT06355986?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 2,500 participants. The study started on 2026-12-30. Estimated completion is 2027-07-30.
What interventions are being tested in trial NCT06355986?
The interventions under investigation include: Alert-based computerized decision support (BEHAVIORAL).
Who is sponsoring clinical trial NCT06355986?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06355986's enrollment target sits among peer trials
2,500 44th of 2000 higher than 1,956 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI